Activated human platelet products induce proarrhythmic effects in ventricular myocytes

Jonas S S G de Jong1, Arie O Verkerk, Marcel M G J van Borren

  • 1Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Insights

Activated platelet products prolong cardiac action potentials and disrupt calcium handling, potentially triggering fatal arrhythmias during heart attacks. This research uncovers a key mechanism in sudden cardiac death.

Area of Science:

  • Cardiovascular Physiology
  • Cardiac Electrophysiology
  • Platelet Biology

Background:

  • Sudden cardiac death, often due to ventricular fibrillation (VF) during ischemia, is a major cause of mortality.
  • Platelet activation is implicated in increasing VF susceptibility in ischemic heart tissue, but the underlying mechanisms are unclear.

Purpose of the Study:

  • To investigate the effects of activated blood platelet products (ABPPs) on cardiac electrophysiology and intracellular calcium (Ca(2+)(i)) homeostasis.
  • To elucidate the cellular mechanisms by which ABPPs may contribute to arrhythmias in ischemic conditions.

Main Methods:

  • Human platelets were activated, and secreted products (ABPPs) were applied to isolated rabbit ventricular myocytes.
  • Electrophysiological properties (membrane potential) and Ca(2+)(i) transients were measured using patch-clamp and indo-1 fluorescence.
  • Specific ion channel currents, including L-type Ca(2+) current (I(Ca,L)), were analyzed.

Main Results:

  • ABPPs prolonged action potential duration and induced early and delayed afterdepolarizations.
  • ABPPs significantly increased I(Ca,L) density and enhanced systolic Ca(2+)(i), Ca(2+)(i) transient amplitude, and sarcoplasmic reticulum Ca(2+) content.
  • Other major ion currents and Na(+)-Ca(2+) exchange current remained unaffected.

Conclusions:

  • Secreted products from activated human platelets alter cardiac electrophysiology by modulating I(Ca,L) and Ca(2+)(i) homeostasis.
  • These alterations lead to action potential prolongation and afterdepolarizations, which may promote reentrant arrhythmias in scenarios like coronary thrombosis.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...